BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Basta F, Fasola F, Triantafyllias K, Schwarting A. Systemic Lupus Erythematosus (SLE) Therapy: The Old and the New. Rheumatol Ther 2020;7:433-46. [PMID: 32488652 DOI: 10.1007/s40744-020-00212-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Du L, Feng Y, Wang C, Shi X, Wen C, He Z, Zhang Y. Jieduquyuziyin prescription promotes the efficacy of prednisone via upregulating Nrf2 in MRL/lpr kidneys. J Ethnopharmacol 2022;298:115643. [PMID: 36031105 DOI: 10.1016/j.jep.2022.115643] [Reference Citation Analysis]
2 Cheng H, Zhang X, Yang H, Yu Z, Yan C, Gao C, Wen H. Efficacy and safety of belimumab/low-dose cyclophosphamide therapy in moderate-to-severe systemic lupus erythematosus. Front Immunol 2022;13:911730. [DOI: 10.3389/fimmu.2022.911730] [Reference Citation Analysis]
3 Yuan W, Guan F. Thrombosis and Anticoagulation Therapy in Systemic Lupus Erythematosus. Autoimmune Dis 2022;2022:3208037. [PMID: 35795725 DOI: 10.1155/2022/3208037] [Reference Citation Analysis]
4 de la Rubia Navarro M, Ivorra Cortés JR, Grau García E, Román Ivorra JA. Efectiveness of belimumab in the treatment of lupus nephritis: analysis of 8 cases. Med Clin (Barc) 2022:S0025-7753(22)00267-6. [PMID: 35811138 DOI: 10.1016/j.medcli.2022.05.003] [Reference Citation Analysis]
5 He H, Luo M, Xiong J. Efficacy of bortezomib in reduction of systemic lupus erythematosus disease activity index score: A meta-analysis. Eur J Inflamm 2022;20:1721727X2211051. [DOI: 10.1177/1721727x221105152] [Reference Citation Analysis]
6 Wen X, Xu D, Yuan S, Zhang J. Transverse myelitis in systemic lupus erythematosus: A case report and systematic literature review. Autoimmun Rev 2022;:103103. [PMID: 35452852 DOI: 10.1016/j.autrev.2022.103103] [Reference Citation Analysis]
7 Merrill JT, Werth VP, Furie R, van Vollenhoven R, Dörner T, Petronijevic M, Velasco J, Majdan M, Irazoque-Palazuelos F, Weiswasser M, Korish S, Ye Y, Gaudy A, Schafer PH, Liu Z, Agafonova N, Delev N. Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus. N Engl J Med 2022;386:1034-45. [PMID: 35294813 DOI: 10.1056/NEJMoa2106535] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 11.0] [Reference Citation Analysis]
8 Zhang L, Guan C, Ye Z, Lu Y. Unilateral branch retinal artery occlusion in a patient with systemic lupus erythematosus: A case report. Medicine (Baltimore) 2022;101:e29005. [PMID: 35451396 DOI: 10.1097/MD.0000000000029005] [Reference Citation Analysis]
9 Zhai J, Zhang P, Zhang N, Luo Y, Wu Y. Analysis of WDFY4 rs7097397 and PHLDB1 rs7389 polymorphisms in Chinese patients with systemic lupus erythematosus. Clin Rheumatol 2022. [PMID: 35188604 DOI: 10.1007/s10067-022-06103-4] [Reference Citation Analysis]
10 Kawato Y, Fukahori H, Nakamura K, Kanno A, Kubo K, Hiramitsu M, Matsuda T, Hanada Y, Furukawa T, Nakajima Y, Kinugasa F, Morokata T. Potential benefit of the cathepsin S inhibitor, ASP1617, as a treatment for systemic lupus erythematosus. European Journal of Pharmacology 2022. [DOI: 10.1016/j.ejphar.2022.174826] [Reference Citation Analysis]
11 Rajasinghe LD, Bates MA, Benninghoff AD, Wierenga KA, Harkema JR, Pestka JJ. Silica Induction of Diverse Inflammatory Proteome in Lungs of Lupus-Prone Mice Quelled by Dietary Docosahexaenoic Acid Supplementation. Front Immunol 2022;12:781446. [DOI: 10.3389/fimmu.2021.781446] [Reference Citation Analysis]
12 Sánchez ARP, Voskuyl AE, van Vollenhoven RF. Treat-to-target in systemic lupus erythematosus: advancing towards its implementation. Nat Rev Rheumatol 2022. [PMID: 35039665 DOI: 10.1038/s41584-021-00739-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
13 Janssen LMF, Ghosh M, Lemaire F, Michael Pollard K, Hoet PHM. Exposure to silicates and systemic autoimmune-related outcomes in rodents: a systematic review. Part Fibre Toxicol 2022;19:4. [PMID: 34996462 DOI: 10.1186/s12989-021-00439-6] [Reference Citation Analysis]
14 Ferreté-Bonastre AG, Cortés-Hernández J, Ballestar E. What can we learn from DNA methylation studies in lupus? Clin Immunol 2022;234:108920. [PMID: 34973429 DOI: 10.1016/j.clim.2021.108920] [Reference Citation Analysis]
15 He Z, Zhou S, Yang M, Zhao Z, Mei Y, Xin Y, Zhao M, Wu H, Lu Q. Comprehensive analysis of epigenetic modifications and immune-cell infiltration in tissues from patients with systemic lupus erythematosus. Epigenomics 2022;14:81-100. [PMID: 34913398 DOI: 10.2217/epi-2021-0318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Wang B, Chen S, Li Y, Xuan J, Liu Y, Shi G. Targeted Therapy for Primary Sjögren's Syndrome: Where are We Now? BioDrugs 2021;35:593-610. [PMID: 34731460 DOI: 10.1007/s40259-021-00505-7] [Reference Citation Analysis]
17 Emorinken A, Erameh CO, Eluehike SU, Dic-Ijiewere MO, Ugheoke AJ. Coexistence of Systemic Lupus Erythematosus and Syringomyelia: A Case From a Rural Center in Nigeria. Cureus 2021;13:e17679. [PMID: 34650856 DOI: 10.7759/cureus.17679] [Reference Citation Analysis]
18 Ahmed AR, Aksoy M. IgM Deficiency in Autoimmune Blistering Mucocutaneous Diseases Following Various Treatments: Long Term Follow-Up and Relevant Observations. Front Immunol 2021;12:727520. [PMID: 34646266 DOI: 10.3389/fimmu.2021.727520] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Port A, Shaw JV, Klopp-Schulze L, Bytyqi A, Vetter C, Hussey E, Mammasse N, Ona V, Bachmann A, Strugala D, Reh C, Goteti K. Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll-like receptors 7 and 8. Pharmacol Res Perspect 2021;9:e00842. [PMID: 34414672 DOI: 10.1002/prp2.842] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
20 Klumb EM, Scheinberg M, Souza VA, Xavier RM, Azevedo VF, McElwee E, Restrepo MR, Monticielo OA. The landscape of systemic lupus erythematosus in Brazil: An expert panel review and recommendations. Lupus 2021;:9612033211030008. [PMID: 34255586 DOI: 10.1177/09612033211030008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Levy RA, Gonzalez-Rivera T, Khamashta M, Fox NL, Jones-Leone A, Rubin B, Burriss SW, Gairy K, Maurik AV, Roth DA. 10 Years of belimumab experience: What have we learnt? Lupus 2021;:9612033211028653. [PMID: 34238087 DOI: 10.1177/09612033211028653] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
22 Cheng H, Zhao CS, Yan CL, Gao C, Wen HY. Efficacy of Belimumab for refractory systemic lupus erythematosus (SLE) involving the central nervous system. Eur J Intern Med 2021:S0953-6205(21)00211-9. [PMID: 34226115 DOI: 10.1016/j.ejim.2021.06.012] [Reference Citation Analysis]
23 Nimesh S, Ahmad MI, Dhama S, Kumar P, Akram M, Hasaroeih NEN. Systemic Lupus Erythematosus Disease: An Overview of the Clinical Approach to Pathogenesis, Diagnosis, and Treatment. Borneo J Pharm 2021;4:91-8. [DOI: 10.33084/bjop.v4i2.1950] [Reference Citation Analysis]
24 Miao C, Wang X, Zhou W, Huang J. The emerging roles of exosomes in autoimmune diseases, with special emphasis on microRNAs in exosomes. Pharmacol Res 2021;169:105680. [PMID: 34010670 DOI: 10.1016/j.phrs.2021.105680] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
25 Wang J, Chen Q, Zhang Z, Wang S, Wang Y, Xiang M, Liang J, Xu J. Azithromycin alleviates systemic lupus erythematosus via the promotion of M2 polarisation in lupus mice. Cell Death Discov 2021;7:82. [PMID: 33863874 DOI: 10.1038/s41420-021-00466-4] [Reference Citation Analysis]
26 Basta F, Möckel T, Petersohn J, Meineck M, Triantafyllias K, Engel S, Weinmann A, Luessi F, Weinmann-Menke J, Schwarting A. The relationship between BAFF serum levels, anti-NMDAR autoantibodies and fatigue in patients with systemic lupus erythematosus and multiple sclerosis. Autoimmun Rev 2021;20:102802. [PMID: 33727153 DOI: 10.1016/j.autrev.2021.102802] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
27 Lebreton V, Bourcier B, Cosson K, Lagarce F, Spiesser-robelet L, Vrignaud S. New liquid oral formulations of hydroxychloroquine: a physicochemical stability study. Pharmaceutical Technology in Hospital Pharmacy 2021;6:20200013. [DOI: 10.1515/pthp-2020-0013] [Reference Citation Analysis]
28 Möckel T, Basta F, Weinmann-Menke J, Schwarting A. B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE). Autoimmun Rev 2021;20:102736. [PMID: 33333233 DOI: 10.1016/j.autrev.2020.102736] [Cited by in Crossref: 4] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
29 Xu X, Lin A, Wang X. Seizures in steroid-responsive encephalopathy. Neurol Sci 2021;42:521-30. [PMID: 33219869 DOI: 10.1007/s10072-020-04891-8] [Reference Citation Analysis]